Adrenal Hyperplasia, Congenital Clinical Trial
Official title:
A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia
The purpose of this study is to develop a more physiological approach to the management of
children and adolescents with salt wasting Congenital Adrenal Hyperplasia.
We will administer the glucocorticosteroid via insulin infusion pump to see whether this
treatment will improve the serum hormone concentrations.
The adrenal gland is a small organ of the body. It produces very important chemicals called
hormones. One of these hormones, cortisol (the stress hormone) helps the body fight
diseases. The other hormone is the aldosterone helps to maintain the normal amount of salt
and water in the body. The third type of hormones are the androgens or male hormones, which
cause some of the changes during puberty, like the growth of body hair and pimples.
The salt wasting Congenital Adrenal Hyperplasia or CAH disease is a disease of the adrenal
gland. Patients with this disease cannot make cortisol or the aldosterone. As a result,
their body cannot fight diseases and cannot keep normal amounts of salt and water in the
body. At the same time, the gland makes too much of the male hormones, which is bad for the
body because too much male hormone slows down growth, increases the growth of body hair, and
causes pimples and abnormal period in girls.
Patients with this disease have to take medications every day. However, the treatment does
not work very well, because usually the patients do not have the right amount of hormone in
their body. Usually the body gets too much hormone right after taking the pills. A couple of
hours later the body has too little of the hormones, because in the meantime the body gets
rid of the medication.The healthy adrenal gland makes the hormones throughout the day in
different amounts. The patients with this disease take the medication only a couple of times
a day. They take the Florinef tablet once a day and the Cortisol tablet two or three times a
day. The treatment that we use today by mouth cannot copy the natural hormone productions of
the adrenal gland. Because of this it does not make much of a difference in the patient's
life.
We would like to improve the treatment and find out the effect of a new treatment. In this
study we will try to imitate the body's normal hormone production and will give the
medication via an insulin pump to see if this treatment method will decrease the male
hormones in the blood. This study will help us to develop a new and better treatment for
children and adolescents.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03162172 -
Growth Hormone (GH) in Congenital Adrenal Hyperplasia
|
N/A | |
Recruiting |
NCT00617292 -
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers
|
N/A | |
Recruiting |
NCT05228652 -
Questionnaire Study to Assess the Outcomes of the Management of Congenital Adrenal Hyperplasia Individuals
|
||
Recruiting |
NCT01771328 -
Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia
|
Phase 2 | |
Active, not recruiting |
NCT01862380 -
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.
|
N/A | |
Completed |
NCT03589144 -
LC-MS / MS Adrenal Steroids Assayed on Dried Blot Spot for the Congenital Adrenal Hyperplasia Neonatal Screening (SPECTROSPOT)
|
||
Completed |
NCT01488721 -
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System
|
N/A | |
Recruiting |
NCT00694525 -
Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia
|
N/A | |
Completed |
NCT00621985 -
Dexamethasone Treatment of Congenital Adrenal Hyperplasia
|
Phase 2 |